Print

Purpose

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 250 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female participants must be ≥ 18 years of age - Participants with a documented diagnosis of PA that fulfils the criteria defined in the 2016 or 2025 Endocrine Society Guidelines. - Participants willing and able to cease dosing of MRA or potassium sparing diuretics per study requirement for participants taking an MRA or potassium sparing diuretic at Screening. - eGFR ≥ 45 mL/min/1.73m2 at Screening - Serum potassium level ≥ 3.0 and < 5.0 mmol/L at Screening determined as per the central laboratory. - Have a stable regimen of antihypertensive medications for at least 4 weeks prior to randomisation - Mean seated SBP on AOBPM of ≥ 135 mmHg and ≤ 170 mmHg and mean DBP of ≤ 105 mmHg. - Serum potassium (local lab) > 3.0 mmol/L at randomization.

Exclusion Criteria

  • If not taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP > 170 mmHg or mean seated DBP >105 mmHg (on AOBPM). If taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP > 160 mmHg or mean seated DBP ≥ 100 mmHg. - Previous surgical intervention for an adrenal adenoma or have a planned adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study. - Has the following known secondary causes of HTN: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation. - Serum sodium level < 135 mmol/L at Screening, determined as per central laboratory. - New York Heart Association functional HF class IV at Screening. - Persistent atrial fibrillation. - Treatment with any MRA or potassium-sparing diuretic within 2 weeks prior to Randomisation.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Baxdrostat 		Baxdrostat administered orally, once daily (QD).
  • Drug: Baxdrostat
    Baxdrostat tablet administered orally, once daily (QD).
    Other names:
    • CIN-107
Placebo Comparator
Placebo 		Matching placebo administered orally, once daily (QD).
  • Drug: Placebo
    Placebo tablet matching baxdrostat, administered orally, once daily (QD).

Recruiting Locations

Research Site
Chicago, Illinois 60611

Research Site
Olive Branch, Mississippi 38654

Research Site
Columbia, South Carolina 29203

More Details

Status
Recruiting
Sponsor
AstraZeneca

Study Contact

AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.